[Prognostic value of PSA kinetics in locally advanced prostate cancer treated by maximal androgen blockade combined with brachytherapy].

Objective: To evaluate the effect of post-treatment PSA kinetics on the prognosis of prostate cancer (PCa).

Methods: We retrospectively reviewed the clinical data of 114 cases of locally advanced PCa treated by maximal androgen blockade (MAB) combined with brachytherapy, and analyzed the association of the changes in PSA kinetics with the prognosis of the patients.

Results: The median survival time of the patients was 81 (15 - 144) months, with 1-, 3- and 5-year survival rates of 91.

[Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade].

Objective: To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.

Methods: A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed.

Epithelial-mesenchymal transition and migration of prostate cancer stem cells is driven by cancer-associated fibroblasts in an HIF-1α/β-catenin-dependent pathway.

Although cancer stem cells (CSCs) play a crucial role in seeding the initiation of tumor progression, they do not always possess the same potent ability as tumor metastasis. Thus, precisely how migrating CSCs occur, still remains unclear. In the present study, we first comparatively analyzed a series of prostate CSCs, which exhibited a dynamically increasing and disseminating ability in nude mice.